Key Takeaways
- About 1 in 9 U.S. adults currently takes a GLP-1 drug, per Gallup data cited by the report.
- The panel says obesity rates may be falling while severe obesity keeps rising.
- It urges wider coverage and stronger oversight of compounded copies.
The drugs are reshaping obesity rates — but access is lagging behind
Roughly 1 in 9 U.S. adults is taking a GLP-1 drug such as Ozempic or Zepbound, according to a JAMA Summit Report on obesity published November 17, 2026. The report, led by researchers including Anne Cappola, David Angus and Rexford Ahima, draws on Gallup data and points to an important shift: U.S. obesity rates may be falling for the first time in decades — largely because of these medicines. At the same time, severe obesity continues to rise.
What the report found
The findings came from a JAMA-convened summit in Chicago in May 2026, bringing together patients, clinicians, scientists, economists, policy experts and industry representatives. The report was presented at ObesityWeek 2026.
The panel describes GLP-1 medicines as the first scalable, highly effective drug treatment for obesity. Trials have also linked them to lower cardiovascular risk and slower progression of chronic kidney disease. Still, the scale of obesity remains enormous. Nearly half of U.S. adults and 1 in 5 U.S. children meet the medical definition of obesity, and more than a billion people worldwide live with it.
Access is the problem
Coverage gaps and prior-authorization hurdles often stand between patients and treatment. The panel urges payers to fund comprehensive care — lifestyle support, medication and surgery together — and to treat obesity as the chronic disease it is. Two programs could be expanded, the report says: the Medicare GLP-1 Bridge, which began July 1, 2026 with a $50 monthly copay for eligible beneficiaries and runs through the end of 2027; and Medicaid's BALANCE model.
The compounded-drug warning
The report also calls for stronger oversight of compounded copies of GLP-1 drugs sold outside of shortage conditions. This comes as a growing direct-to-consumer market offers both approved products and unapproved compounded versions. Another gap is quieter but striking: fewer than 1% of people eligible for weight-loss surgery ever receive it.
On prevention, the panel points to structural measures — food labelling, limits on marketing to children and school nutrition standards — and to care that measures success by more than the number on the scale. One striking comparison: people taking GLP-1 drugs consume roughly 200 to 400 fewer calories a day. Meanwhile, the average U.S. per-person calorie supply has climbed from about 3,200 to about 4,000 calories a day since the 1970s.
This report is an expert consensus paper, not a clinical trial. Its prevalence and calorie figures come from the sources the panel cites, and its policy recommendations reflect the panel's judgment rather than tested interventions.
This article summarizes an expert report and is not medical advice. Decisions about weight-loss medication belong with your own clinician, who knows your history.
The Twikup Take
When one in nine adults is already on a drug class that barely existed five years ago, the story stops being about a medicine and becomes about a system: who gets coverage, who gets a compounded copy of uncertain quality, and who gets nothing. The JAMA panel's real message is that the science sprinted ahead — and access, oversight and prevention are still tying their shoes.
Image: Illustrative image.
